Syndax Q3 net loss $35.4M; revumenib Phase 1 shows 30% CR/CRh rate, 9.1 mo median durability

Syndax Pharmaceuticals Inc

2022-Q3 EPS reported -$1.84

Net loss $35.4M ($0.58 per share) vs $20.6M ($0.40) prior year; cash $337.8M at Sep 30.
Revumenib Phase 1 CR/CRh rate 30% (18/60); median response 9.1 months; 75% of transplanted patients in remission.
Enrollment complete in pivotal AGAVE-201 trial of axatilimab in cGVHD; topline data expected mid-2023.
Lowered FY 2022 R&D expense guidance to $115-125M and total op ex to $145-155M, citing axatilimab cost sharing.
On track for revumenib NDA and axatilimab BLA filings by end of 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Syndax Pharmaceuticals Inc reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-22-021838

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.